$12.23
6.58% yesterday
Nasdaq, Nov 25, 09:43 pm CET
ISIN
US0465131078
Symbol
ATRA
Sector
Industry

Atara Biotherapeutics Inc Target price 2024 - Analyst rating & recommendation

Atara Biotherapeutics Inc Classifications & Recommendation:

Buy
40%
Hold
40%
Sell
20%

Atara Biotherapeutics Inc Price Target

Target Price $14.75
Price $12.12
Potential
Number of Estimates 4
4 Analysts have issued a price target Atara Biotherapeutics Inc 2025 . The average Atara Biotherapeutics Inc target price is $14.75. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 5 analysts: 2 Analysts recommend Atara Biotherapeutics Inc to buy, 2 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Atara Biotherapeutics Inc stock has an average upside potential 2025 of . Most analysts recommend the Atara Biotherapeutics Inc stock at Buy or hold.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 8.57 112.52
86.52% 1,212.91%
EBITDA Margin -3,085.76% -77.78%
654.53% 97.48%
Net Margin -4,365.61% -7.73%
21,484.29% 99.82%

5 Analysts have issued a sales forecast Atara Biotherapeutics Inc 2024 . The average Atara Biotherapeutics Inc sales estimate is

$113m
Unlock
. This is
12.02% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$136m 35.80%
Unlock
, the lowest is
$76.2m 24.14%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $8.6m 86.52%
2024
$113m 1,212.91%
Unlock
2025
$104m 7.55%
Unlock
2026
$86.6m 16.77%
Unlock
2027
$209m 141.60%
Unlock
2028
$151m 27.81%
Unlock

1 Analyst has issued an EBITDA forecast Atara Biotherapeutics Inc 2024 . The average Atara Biotherapeutics Inc EBITDA estimate is

$-87.5m
Unlock
. This is
23.40% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-87.5m 23.40%
Unlock
, the lowest is
$-87.5m 23.40%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-264m 1.72%
2024
$-87.5m 66.91%
Unlock
2025
$18.9m 121.54%
Unlock
2026
$-66.3m 451.53%
Unlock

EBITDA Margin

2023 -3,085.76% 654.53%
2024
-77.78% 97.48%
Unlock
2025
18.13% 123.31%
Unlock
2026
-76.56% 522.28%
Unlock

2 Atara Biotherapeutics Inc Analysts have issued a net profit forecast 2024. The average Atara Biotherapeutics Inc net profit estimate is

$-8.7m
Unlock
. This is
94.09% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-4.6m 96.88%
Unlock
, the lowest is
$-12.8m 91.31%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-374m 2,809.82%
2024
$-8.7m 97.67%
Unlock
2025
$-39.1m 348.97%
Unlock
2026
$-23.4m 40.19%
Unlock
2027
$2.9m 112.54%
Unlock

Net Margin

2023 -4,365.61% 21,484.29%
2024
-7.73% 99.82%
Unlock
2025
-37.55% 385.77%
Unlock
2026
-26.99% 28.12%
Unlock
2027
1.40% 105.19%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -65.18 -1.52
2,809.82% 97.67%
P/E negative
EV/Sales 0.80

2 Analysts have issued a Atara Biotherapeutics Inc forecast for earnings per share. The average Atara Biotherapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-1.52
Unlock
. This is
94.08% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-0.80 96.88%
Unlock
, the lowest is
$-2.23 91.31%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-65.18 2,809.82%
2024
$-1.52 97.67%
Unlock
2025
$-6.81 348.03%
Unlock
2026
$-4.07 40.23%
Unlock
2027
$0.51 112.53%
Unlock

P/E ratio

Current -0.47 104.35%
2024
-8.00 1,602.13%
Unlock
2025
-1.78 77.75%
Unlock
2026
-2.98 67.42%
Unlock
2027
23.76 897.32%
Unlock

Based on analysts' sales estimates for 2024, the Atara Biotherapeutics Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 0.90 84.07%
2024
0.80 10.58%
Unlock
2025
0.87 8.16%
Unlock
2026
1.05 20.15%
Unlock
2027
0.43 58.61%
Unlock
2028
0.60 38.53%
Unlock

P/S ratio

Current 0.70 95.25%
2024
0.62 10.73%
Unlock
2025
0.67 8.17%
Unlock
2026
0.81 20.16%
Unlock
2027
0.33 58.61%
Unlock
2028
0.46 38.50%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today